Allogeneic hematopoietic stem cell transplantation (HSCT) tests the hypothesis that the replacement of a 'diseased' autoreactive immunological and stem cell compartment with one that is not autoreactive (but potentially alloreactive) can cure severe autoimmune diseases. The primary risks of allogeneic HSCT are the morbidity and morality associated with delayed immune reconstitution and GVHD. Although the risk of complications and mortality is greater than autologous HSCT, studies of allogeneic HSCT should be conducted in selected cases because there is a greater potential for sustained remissions. This review will discuss the anticipated results from allogeneic HSCT by summarizing outcomes in aplastic anemia and chronic myelogenous leukemia as well as a brief description of Seattle's experience with allogeneic HSCT in the first two patients with systemic sclerosis.
It is currently unclear what environmental and genetic factors are contributing to the development of human autoimmune diseases. However, based on the preclinical data and anecdotal clinical experience with allogeneic hematopoietic stem cell transplantation (HSCT), a substantial therapeutic effect is expected (Table 1 ). An immunologically competent donor hematopoietic stem cell graft is effective antihost T-cell therapy, establishing full donor T-cell chimerism after myeloablative conditioning in almost all cases.
In one multicenter study of a nonmalignant disease (aplastic anemia), which included 94 patients, the probability of survival was 0.88 at 6 years after marrow transplantation from HLA-identical siblings (Figure 1 ). 1 The incidence and prevalence of acute and chronic GVHD was less than 30%, respectively ( Figure 2 ). Most cases of extensive chronic GVHD resolved over time with only eight patients requiring immunosuppressive therapy at a median of 2.6 years of follow-up. In a group of 101 patients with chronic myelogenous leukemia in chronic phase, who received conditioning with busulfan (targeted to a steady-state clearance of 900 ng/ml) and cyclophosphamide, the probability of survival was 85% at 5 years after HSCT from HLA-identical siblings ( Figure 3 ; unpublished data from FHCRC). When extrapolated to other diseases, it must be cautioned that the outcome after allogeneic HSCT is heavily dependent on the disease status and the medical condition of the patient at the time of transplant.
Allogeneic HSCT for scleroderma
The inclusion criteria for the study of allogeneic HSCT for systemic sclerosis (SSc) are similar to those reported for the study of autologous HSCT. 2, 3 To minimize risks associated with the treatment, younger patients (o45-55 years of age) should be selected for inclusion in the protocol until it is clear what the safety concerns are and we have some efficacy data. 4, 5 In general, younger patients tolerate the toxicities from myeloablative conditioning better and have less problems with severe GVHD, although some studies have shown comparable outcomes in older patients. [6] [7] [8] The patients should have good renal function at baseline so that GVHD prophylaxis will not be compromised.
There has been enthusiasm for the use of nonmyeloablative conditioning regimens because of the low risk of regimen-related toxicities especially in older patients. However, it should be stated that this approach might not have an advantage over myeloablative conditioning for the younger patient in otherwise good medical condition since GVHD still remains a significant issue determining outcome. In addition, since the mixed chimeric state may persist for many months after nonmyeloablative HSCT, it is unclear if the autoimmune disease will remain active or progress while elements of the host immune system persist.
Owing to extensive prior transplant experience, the combination of busulfan and cyclophosphamide was chosen as conditioning regimen. Since engraftment and not the eradication of malignancy is the primary goal of the conditioning, the busulfan steady-state clearance can be targeted to a level of 600-700 ng/ml. High-dose total body irradiation (TBI) was not used for the conditioning regimen since there was a concern for pulmonary toxicity and the intent was to establish a stem cell graft for which busulfan and cyclophosphamide were adequate.
Marrow was the source for the stem cell graft. Although studies comparing marrow with peripheral blood stem cells (PBSC) in patients with hematological malignancies have shown that survival was improved in the PBSC group, the incidence of chronic GVHD was higher and required more treatment. The lower relapse rate contributed significantly to the improvement in overall survival. Since relapse of malignant disease is not an issue in the studies of autoimmune disease, it may be reasonable to use marrow to reduce the risk of chronic GVHD.
Persisting clinical manifestations of scleroderma may confound the evaluation of transplant-related complications. There are some similarities in the manifestations of SSc and chronic GVHD. 9 However, the many differences between the clinical manifestations of these two diseases are expected to permit an adequate evaluation of the response of SSc to allogeneic HSCT (Table 2) . Although skin involvement is the most common manifestation of chronic GVHD, less than half of the patients develop this complication after HSCT from HLA-identical siblings and only 7% of patients with chronic GVHD develop scleroderma. Two patients with severe SSc were treated with conventional allogeneic HSCT from HLA-identical siblings. Both patients had extensive scleroderma and pulmonary fibrosis. The first patient is greater than 3 years after transplantation and greater than 2 years after discontinuation of immunosuppressive therapy. There was a significant improvement in the extent of the scleroderma and forced vital capacity compared to baseline but the DLCO remained unchanged. The second patient had a significant improvement in the skin even though chronic GVHD developed. While tapering immunosuppressive therapy, the patient developed overwhelming Pseudomonas sepsis and died 18 months after HSCT.
Although the experience is still limited, allogeneic HSCT is likely to be effective treatment for severe autoimmune diseases including SSc. Complications which occur after allogeneic HSCT for severe autoimmune diseases may be different than those typically observed for hematological malignancies. For patients with SSc this may include skin toxicity associated with the conditioning regimen and renal crisis. Pilot studies of conventional allogeneic HSCT for severe autoimmune diseases are warranted for young patients with good renal function, high risk of mortality or significant morbidity related to the autoimmune disease, and refractory to standard therapy. 
